Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy

J David Lambeth1

  • 1148 Whitehead Biomedical Research Building, Department of Pathology and Laboratory Medicine, 615 Michael Street, Atlanta, GA 30322, USA. noxdoc@mac.com

Insights

Reactive oxygen species (ROS) generated by Nox enzymes are vital for normal functions but excessive production causes oxidative stress and chronic diseases. Targeting Nox enzymes may benefit aging populations by treating these conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Reactive oxygen species (ROS) are reactive molecules that can damage DNA, proteins, and lipids, leading to oxidative stress and mutations.
  • Nox and Duox enzymes generate ROS for essential physiological functions like innate immunity and signal transduction.
  • Despite their damaging potential, ROS are utilized in normal biological processes, posing a paradox.

Purpose of the Study:

  • To review the physiological roles of Nox enzymes in ROS generation.
  • To explore the association between Nox enzyme-derived ROS and various pathological conditions, particularly chronic diseases.
  • To propose a theoretical framework (antagonistic pleiotropy) explaining the dual role of Nox enzymes in health and disease.

Main Methods:

  • Literature review of Nox enzyme function and associated diseases.
  • Analysis of the role of ROS in physiological and pathological contexts.
  • Discussion of the evolutionary implications of genes involved in ROS production.

Main Results:

  • Nox enzymes are implicated in numerous chronic diseases, including atherosclerosis, hypertension, cancer, and neurodegenerative disorders.
  • In most cases, diseases are linked to the overproduction of ROS by Nox enzymes, causing tissue damage.
  • Rare inherited conditions are exceptions, often related to innate immunity or hormone production.

Conclusions:

  • Nox enzyme overactivity contributes significantly to age-related chronic diseases through excessive ROS production and oxidative stress.
  • The concept of antagonistic pleiotropy helps explain why genes with early-life benefits can cause late-life harm.
  • Targeting Nox enzymes with drugs presents a promising therapeutic strategy for managing chronic diseases in aging populations.

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Epistasis01:39

Epistasis

In addition to multiple alleles at the same locus influencing traits, numerous genes or alleles at different locations may interact and influence phenotypes in a phenomenon called epistasis. For example, rabbit fur can be black or brown depending on whether the animal is homozygous dominant or heterozygous at a TYRP1 locus. However, if the rabbit is also homozygous recessive at a locus on the tyrosinase gene (TYR), it will have an unshaded coat that appears white, regardless of its TYRP1...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...